OneDigital Investment Advisors LLC Purchases 795 Shares of Elevance Health, Inc. (NYSE:ELV)

OneDigital Investment Advisors LLC lifted its position in Elevance Health, Inc. (NYSE:ELV - Free Report) by 11.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,823 shares of the company's stock after purchasing an additional 795 shares during the quarter. OneDigital Investment Advisors LLC's holdings in Elevance Health were worth $2,886,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in ELV. Flagship Wealth Advisors LLC purchased a new position in shares of Elevance Health during the fourth quarter worth about $26,000. OFI Invest Asset Management bought a new stake in Elevance Health during the fourth quarter valued at approximately $29,000. WealthTrak Capital Management LLC purchased a new position in Elevance Health in the 4th quarter worth approximately $29,000. Lee Danner & Bass Inc. bought a new position in shares of Elevance Health in the 4th quarter worth $30,000. Finally, Crews Bank & Trust purchased a new stake in shares of Elevance Health during the 4th quarter valued at $34,000. Institutional investors own 89.24% of the company's stock.

Insider Transactions at Elevance Health

In other Elevance Health news, EVP Charles Morgan Kendrick, Jr. sold 3,504 shares of Elevance Health stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $396.30, for a total value of $1,388,635.20. Following the completion of the transaction, the executive vice president now directly owns 10,116 shares of the company's stock, valued at approximately $4,008,970.80. The trade was a 25.73 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Ronald W. Penczek sold 443 shares of the company's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $415.13, for a total transaction of $183,902.59. Following the completion of the transaction, the chief accounting officer now owns 1,847 shares in the company, valued at approximately $766,745.11. This represents a 19.34 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.29% of the company's stock.

Elevance Health Stock Performance

Shares of Elevance Health stock opened at $416.06 on Wednesday. Elevance Health, Inc. has a 12 month low of $362.21 and a 12 month high of $567.26. The firm has a market capitalization of $94.19 billion, a P/E ratio of 16.25, a P/E/G ratio of 1.18 and a beta of 0.77. The company has a current ratio of 1.45, a quick ratio of 1.50 and a debt-to-equity ratio of 0.71. The business has a fifty day simple moving average of $417.66 and a two-hundred day simple moving average of $409.25.

Elevance Health (NYSE:ELV - Get Free Report) last issued its quarterly earnings results on Tuesday, April 22nd. The company reported $11.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $10.60 by $1.37. The company had revenue of $48.77 billion during the quarter, compared to analysts' expectations of $46.26 billion. Elevance Health had a net margin of 3.38% and a return on equity of 18.28%. On average, equities analysts forecast that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on ELV shares. Mizuho upped their target price on shares of Elevance Health from $455.00 to $505.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 9th. Argus upgraded Elevance Health from a "hold" rating to a "buy" rating and set a $450.00 target price for the company in a research report on Monday, March 17th. Barclays increased their price target on shares of Elevance Health from $501.00 to $512.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. Wells Fargo & Company lowered their price objective on shares of Elevance Health from $483.00 to $478.00 and set an "overweight" rating for the company in a report on Tuesday, January 28th. Finally, Robert W. Baird reaffirmed a "neutral" rating and set a $529.00 target price (down previously from $625.00) on shares of Elevance Health in a report on Tuesday, April 15th. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $508.81.

Elevance Health Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.

Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.